Urine osmolality-guided tolvaptan therapy in decompensated heart failure

Circulation Journal

Volumn 77, Issue 2, 2013, Pages 313-314

  Dohi, Kaoru ^a   Watanabe, Kiyotaka ^a   Ito, Masaaki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; ARGIPRESSIN; CYCLIC AMP; SODIUM ION; TOLVAPTAN;

BODY WEIGHT; CIRCADIAN RHYTHM; DIURESIS; DRUG EFFICACY; DRUG RESPONSE; ECHOCARDIOGRAPHY; EDITORIAL; FLUID RETENTION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; URINE OSMOLALITY; URINE VOLUME;

BENZAZEPINES; DIABETES INSIPIDUS, NEPHROGENIC; DRUG MONITORING; FEMALE; HEART FAILURE; HUMANS; MALE; RECEPTORS, VASOPRESSIN;

EID: 84873803053     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1535     Document Type: Editorial

References (11)

1. Shankar SS, Brater DC. Loop diuretics: From the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284: F11-F21.
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
3. Hiramitsu S, Miyagishima K, Kimura H, Mori K, Shiino K, Yamada A, et al. Management of severe heart failure. Circ J 2009; 73(Suppl A): A36-A41.
4. Paul S. Balancing diuretic therapy in heart failure: Loop diuretics, thiazides, and aldosterone antagonists. Congest Heart Fail 2002; 8: 307-312.
5. Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto D, Yamada S, Yokoshiki H, et al; JCARE-CARD Investigators. Loop diuretic use at discharge is associated with adverse outcomes in hospitalized patients with heart failure: A report from the Japanese cardiac registry of heart failure in cardiology (JCARE-CARD). Circ J 2012; 76: 1920-1927.
6. Burnier M, Brunner HR. Neurohormonal consequences of diuretics in different cardiovascular syndromes. Eur Heart J 1992; 13(Suppl G): 28-33.
7. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25(Suppl 1): S57-S65.
8. Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-469.
9. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: Association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
10. Noh JY, Han DH, Yoon JA, Kim MH, Kim SE, Ko IG, et al. Circadian rhythms in urinary functions: Possible roles of circadian clocks? Int Neurol J 2011; 15: 64-73.
11. Firsov D, Bonny O. Circadian regulation of renal function. Kidney Int 2010; 78: 640-645.